德尔塔
您当前所在位置:首页 > 最新产品 > 热门产品

Gatifloxacin-d3 hydrochloride,加替沙星盐酸盐-d3; AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride「同位素标记抑制剂」

发布时间:2025-09-18     作者:德尔塔生物   分享到:

【产品介绍】:

生物活性:Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Gatifloxacin-d3 hydrochloride 相关抗体:
TOP2A Antibody
DXd Antibody (YA897)
MRP2 Antibody
SN38 Antibody (YA923)
Elongation factor 2 Antibody (YA962)
Elongation factor 2 Antibody (YA964)
PU.1/SPI1 Antibody (YA1116)
Topoisomerase I Antibody (YA2237)
Sulfadimidine Antibody (YA906)
Elongation factor 2 Antibody (YA963)
Anthrax Protective gen Antibody (YA1060)
Elongation factor 1 gamma Antibody (YA2004)
Pulmonary Surfactant Associated Protein D Antibody (YA2107)
Cathelicidin Antibody (YA2380)
Elongation Factor Ts Antibody (YA2524)
Elongation Factor 1A2 Antibody (YA2879)
BPI Antibody (YA3068)
MetRS Antibody (YA3196)
分子量:414.87
Formula:C19H20D3ClFN3O4
非标记 CAS:121577-32-0
中文名称:加替沙星盐酸盐-d3
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (531 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Takei M, et al. Inhibitory activities of Gatifloxacin hydrochloride (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Antimicrob Agents Chemother. 1998 Oct;42(10):2678-81.
 [Content Brief]
[3]. Fukuda H, et al. Antibacterial activity of Gatifloxacin hydrochloride (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Aug;42(8):1917-22.
 [Content Brief]
[4]. Yamada C, et al. Gatifloxacin hydrochloride acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol. 2006 Dec 28;553(1-3):67-72. Epub 2006 Sep 28.
 [Content Brief]
[5]. Daw-Garza A, et al. In vivo therapeutic effect of Gatifloxacin mesylate on BALB/c mice infected with Nocardia brasiliensis.Antimicrob Agents Chemother. 2008 Apr;52(4):1549-50.
 [Content Brief]